Evidence map›Paper›PMID 39512302›Full record

ArticleAdvances in pharmacological and pharmaceutical sciences2024

Inhibitory Effect of (2

Hilwan Yuda Teruna, Kamal Rullah, Rudi Hendra, Rahayu Utami, Deri Islami, Siti Munirah Mohd Faudzi, Mohd Fadhlizil Fasihi Mohd Aluwi, Kok Wai Lam

Abstract read
In one paragraph

Article in Advances in pharmacological and pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hilwan Yuda TerunaDepartment of Chemistry, Faculty Mathematics and Natural Sciences, Universitas Riau, Pekanbaru 28293, Indonesia.ORCID https://orcid.org/0000-0001-6363-5239
Kamal RullahDepartment of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia 25200, Kuantan, Pahang, Malaysia.ORCID https://orcid.org/0000-0001-6856-9373
Rudi HendraDepartment of Chemistry, Faculty Mathematics and Natural Sciences, Universitas Riau, Pekanbaru 28293, Indonesia.ORCID https://orcid.org/0000-0002-1103-8261
Rahayu UtamiDepartment of Pharmacy, Sekolah Tinggi Ilmu Farmasi Riau, Pekanbaru 28293, Indonesia.ORCID https://orcid.org/0000-0001-6554-3987
Deri IslamiDepartment of Pharmacy, Faculty of Medicine and Health Sciences, Universitas Abdurrab, Pekanbaru 28292, Indonesia.ORCID https://orcid.org/0009-0002-2390-9535
Siti Munirah Mohd FaudziNatural Medicines and Product Research Laboratory (NaturMeds), Institute of Bioscience, Universiti Putra Malaysia, UPM Serdang, Selangor 43400, Malaysia.ORCID https://orcid.org/0000-0001-8043-798X
Mohd Fadhlizil Fasihi Mohd AluwiFaculty of Industrial Sciences and Technology, Universiti Malaysia Pahang, Gambang 26300, Pahang, Malaysia.ORCID https://orcid.org/0000-0003-0729-768X
Kok Wai LamDrugs and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.ORCID https://orcid.org/0000-0002-4366-6772

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pinocembrin (PCB), a flavonoid known for its anti-inflammatory properties, has been approved for various clinical trial applications. To evaluate deeper into the anti-inflammatory potential of the specific enantiomer of natural PCB, we conducted the first investigation into the efficacy of the pure enantiomer (2

Identifiers

PMID39512302
PMCPMC11540893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.